337519-87-6

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-amino-2-chlorophenoxy)-, 1,1-dimethylethyl ester
• CAS NO: 337519-87-6
• Molecular Formula: C16H23ClN2O3
• Molecular Weight: 326.823
• Mol File: 337519-87-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-amino-2-chlorophenoxy)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-amino-2-chlorophenoxy)-, 1,1-dimethylethyl ester(337519-87-6)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-amino-2-chlorophenoxy)-, 1,1-dimethylethyl ester(337519-87-6)

Safety Data

• Hazardous Substances Data: 337519-87-6(Hazardous Substances Data)

Usage

Antihistamine medication

Cetirizine is used to treat allergy symptoms such as sneezing, itching, and runny nose.

Blocks the action of histamine

It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.

Common uses

It is commonly used to treat hay fever, hives, and other allergic reactions.

Available forms

It is available in various forms including tablets, chewable tablets, and syrup.

Dosing

It is usually taken once a day.

Side effects

Side effects may include drowsiness, dry mouth, and headache.

Upstream product

• 319452-19-2 4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloronitrobenzene 
• 141-78-6 ethyl acetate 
• 7440-66-6 zinc 

Downstream Products

• 337519-88-7 ethyl N-[4-(1-t-butoxycarbonylpiperidin-4-yloxy)-3-chlorophenyl]sulfamoylacetate 

Relevant articles and documents

Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities

To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).

BENZAMIDINE DERIVATIVE

Compounds of general formula (1) and pharmacologically acceptable salts thereof: ???[wherein ??????R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; ??????R2 represents a hydrogen atom or a halogen atom; ??????R3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like; ??????each of R4 and R5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like; ??????R6 represents a heterocycle or the like; ??????each of R7 and R8 represents a hydrogen atom, an alkyl group or the like; ??????n represents 0, 1 or 2] ???exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.